谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

An Open‐label Phase 1/2 Study of Favezelimab Plus Pembrolizumab in Patients with Relapsed/refractory Classical Hodgkin Lymphoma With/without Previous Anti‐pd‐1 Treatment

D. Lavie,N. Johnson,P. Borchmann,A. F. Herrera,A. Avigdor,R. Gasiorowski,G. Gregory,C. Keane,V. Vucinic,M. Bazargan,Y. Herishanu,L. Minuk,I. Tzoran,C. Andreadis,P. Armand,J. Kuruvilla,P. L. Zinzani,R. Marceau West,P. Pillai,P. Marinello,J. Timmerman

Hematological Oncology（2023）

引用 2|浏览25
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要